Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

SGD vs LGND

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SGD
Safe and Green Development Corporation

Real Estate - Development

Real EstateNASDAQ • US
Market Cap$155K
5Y Perf.-99.4%
LGND
Ligand Pharmaceuticals Incorporated

Biotechnology

HealthcareNASDAQ • US
Market Cap$4.13B
5Y Perf.+220.6%

SGD vs LGND — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SGD logoSGD
LGND logoLGND
IndustryReal Estate - DevelopmentBiotechnology
Market Cap$155K$4.13B
Revenue (TTM)$5M$251M
Net Income (TTM)$-14M$49M
Gross Margin16.6%85.9%
Operating Margin-186.2%7.0%
Forward P/E23.6x
Total Debt$10M$7M
Cash & Equiv.$296K$72M

SGD vs LGNDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SGD
LGND
StockSep 23Feb 26Return
Safe and Green Deve… (SGD)1000.6-99.4%
Ligand Pharmaceutic… (LGND)100320.6+220.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: SGD vs LGND

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LGND leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Safe and Green Development Corporation is the stronger pick specifically for growth and revenue expansion. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SGD
Safe and Green Development Corporation
The Real Estate Income Play

SGD is the clearest fit if your priority is growth exposure.

  • Rev growth 27.7%, EPS growth -21.2%
  • 27.7% FFO/revenue growth vs LGND's 27.3%
Best for: growth exposure
LGND
Ligand Pharmaceuticals Incorporated
The Income Pick

LGND carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 1 yrs, beta 0.99
  • 73.0% 10Y total return vs SGD's -99.9%
  • Lower volatility, beta 0.99, Low D/E 0.9%, current ratio 8.93x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthSGD logoSGD27.7% FFO/revenue growth vs LGND's 27.3%
Quality / MarginsLGND logoLGND19.3% margin vs SGD's -277.3%
Stability / SafetyLGND logoLGNDBeta 0.99 vs SGD's 1.69, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)LGND logoLGND+99.1% vs SGD's -80.4%
Efficiency (ROA)LGND logoLGND3.3% ROA vs SGD's -35.9%, ROIC -2.3% vs -50.6%

SGD vs LGND — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SGDSafe and Green Development Corporation

Segment breakdown not available.

LGNDLigand Pharmaceuticals Incorporated
FY 2024
Royalty
27.9%$109M
Intangible Royalty Assets
24.4%$95M
Royalty, Kyprolis
9.8%$38M
Material Sales, Captisol, Core
7.9%$31M
Material Sales, Captisol
7.9%$31M
Contract Revenue
7.0%$27M
Service
6.5%$26M
Other (4)
8.5%$33M

SGD vs LGND — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLGNDLAGGINGSGD

Income & Cash Flow (Last 12 Months)

LGND leads this category, winning 5 of 6 comparable metrics.

LGND is the larger business by revenue, generating $251M annually — 50.5x SGD's $5M. LGND is the more profitable business, keeping 19.3% of every revenue dollar as net income compared to SGD's -2.8%. On growth, SGD holds the edge at +42.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSGD logoSGDSafe and Green De…LGND logoLGNDLigand Pharmaceut…
RevenueTrailing 12 months$5M$251M
EBITDAEarnings before interest/tax-$9M$52M
Net IncomeAfter-tax profit-$14M$49M
Free Cash FlowCash after capex-$3M$31M
Gross MarginGross profit ÷ Revenue+16.6%+85.9%
Operating MarginEBIT ÷ Revenue-186.2%+7.0%
Net MarginNet income ÷ Revenue-2.8%+19.3%
FCF MarginFCF ÷ Revenue-52.9%+12.2%
Rev. Growth (YoY)Latest quarter vs prior year+42.3%+122.8%
EPS Growth (YoY)Latest quarter vs prior year+57.1%+15.6%
LGND leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

SGD leads this category, winning 2 of 3 comparable metrics.
MetricSGD logoSGDSafe and Green De…LGND logoLGNDLigand Pharmaceut…
Market CapShares × price$155,445$4.1B
Enterprise ValueMkt cap + debt − cash$10M$4.1B
Trailing P/EPrice ÷ TTM EPS-0.02x-956.05x
Forward P/EPrice ÷ next-FY EPS est.23.65x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple322.10x
Price / SalesMarket cap ÷ Revenue0.75x24.74x
Price / BookPrice ÷ Book value/share0.18x4.63x
Price / FCFMarket cap ÷ FCF53.41x
SGD leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

LGND leads this category, winning 8 of 8 comparable metrics.

LGND delivers a 5.1% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-7 for SGD. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SGD's 11.95x.

MetricSGD logoSGDSafe and Green De…LGND logoLGNDLigand Pharmaceut…
ROE (TTM)Return on equity-7.0%+5.1%
ROA (TTM)Return on assets-35.9%+3.3%
ROICReturn on invested capital-50.6%-2.3%
ROCEReturn on capital employed-3.1%-2.7%
Piotroski ScoreFundamental quality 0–955
Debt / EquityFinancial leverage11.95x0.01x
Net DebtTotal debt minus cash$10M-$65M
Cash & Equiv.Liquid assets$296,202$72M
Total DebtShort + long-term debt$10M$7M
Interest CoverageEBIT ÷ Interest expense-1.89x22.69x
LGND leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

LGND leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LGND five years ago would be worth $16,102 today (with dividends reinvested), compared to $13 for SGD. Over the past 12 months, LGND leads with a +99.1% total return vs SGD's -80.4%. The 3-year compound annual growth rate (CAGR) favors LGND at 39.5% vs SGD's -89.1% — a key indicator of consistent wealth creation.

MetricSGD logoSGDSafe and Green De…LGND logoLGNDLigand Pharmaceut…
YTD ReturnYear-to-date-14.9%+10.6%
1-Year ReturnPast 12 months-80.4%+99.1%
3-Year ReturnCumulative with dividends-99.9%+171.6%
5-Year ReturnCumulative with dividends-99.9%+61.0%
10-Year ReturnCumulative with dividends-99.9%+73.0%
CAGR (3Y)Annualised 3-year return-89.1%+39.5%
LGND leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

LGND leads this category, winning 2 of 2 comparable metrics.

LGND is the less volatile stock with a 0.99 beta — it tends to amplify market swings less than SGD's 1.69 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LGND currently trades 85.0% from its 52-week high vs SGD's 6.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSGD logoSGDSafe and Green De…LGND logoLGNDLigand Pharmaceut…
Beta (5Y)Sensitivity to S&P 5001.69x0.99x
52-Week HighHighest price in past year$2.36$247.38
52-Week LowLowest price in past year$0.11$98.89
% of 52W HighCurrent price vs 52-week peak+6.9%+85.0%
RSI (14)Momentum oscillator 0–10040.059.3
Avg Volume (50D)Average daily shares traded0226K
LGND leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricSGD logoSGDSafe and Green De…LGND logoLGNDLigand Pharmaceut…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$267.75
# AnalystsCovering analysts17
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

LGND leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SGD leads in 1 (Valuation Metrics).

Best OverallLigand Pharmaceuticals Inco… (LGND)Leads 4 of 6 categories
Loading custom metrics...

SGD vs LGND: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is SGD or LGND a better buy right now?

Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SGD or LGND?

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +61.

0%, compared to -99. 9% for Safe and Green Development Corporation (SGD). Over 10 years, the gap is even starker: LGND returned +73. 0% versus SGD's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SGD or LGND?

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.

99β versus Safe and Green Development Corporation's 1. 69β — meaning SGD is approximately 70% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 12% for Safe and Green Development Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — SGD or LGND?

On earnings-per-share growth, the picture is similar: Ligand Pharmaceuticals Incorporated grew EPS -107.

5% year-over-year, compared to -21. 2% for Safe and Green Development Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — SGD or LGND?

Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning -2.

4% net margin versus -42. 9% for Safe and Green Development Corporation — meaning it keeps -2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LGND leads at -13. 5% versus -31. 6% for SGD. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — SGD or LGND?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is SGD or LGND better for a retirement portfolio?

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

99)). Safe and Green Development Corporation (SGD) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LGND: +73. 0%, SGD: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between SGD and LGND?

These companies operate in different sectors (SGD (Real Estate) and LGND (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SGD is a small-cap quality compounder stock; LGND is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

SGD

High-Growth Disruptor

  • Sector: Real Estate
  • Market Cap > $20B
  • Revenue Growth > 2114%
Run This Screen
Stocks Like

LGND

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 61%
  • Net Margin > 11%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SGD and LGND on the metrics below

Revenue Growth>
%
(SGD: 4229.2% · LGND: 122.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.